ClinicalTrials.gg
RecruitingNCT07360093PENG-PRFUpdated Mar 18, 2026

PENG Block & PENG PRF

An observational study in Osteoarthritis (OA) of the Hip, sponsored by Ankara City Hospital Bilkent. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Ankara City Hospital Bilkent · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
84
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Osteoarthritis with a site in Turkey — 22 open to participants now, 29 under way, none of them phase 3. Osteoarthritis · Turkey.

Planned enrollment
21st of 42
84 · median 84
Started
2026
with 13 others
Observational
42 of 106
10 open now
Primary completion
2027-02
later than 22 of 28 live
Registered
88th of 106
by date
Lead sponsor
6 of 106
Ankara City Hospital Bilkent

Among the 106 studies in Osteoarthritis with a site in Turkey, this one is the 21st largest by planned enrollment of the 42 observational ones that give a count, is one of 14 that started in 2026, is one of 42 observational ones, reaches primary completion later than 22 of the 28 other live ones, and was the 88th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

22 of the 106 studies in Osteoarthritis with a site in Turkey are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Osteoarthritis with a site in Turkey, or all of them as a file.
02

Study summary

The primary aim of this study is to prospectively compare the effects of the pericapsular nerve group (PENG) block alone and the combination of PENG block with pulsed radiofrequency (PRF) on pain intensity in patients with chronic hip pain. As a secondary aim, the effects of both treatment modalities on hip function are intended to be evaluated using valid and reliable functional assessment scales. Through this study, it is aimed to demonstrate the clinical contribution of adding PRF to the PENG block and to identify a more effective and longer-lasting approach for the interventional treatment of chronic hip pain.

Read the detailed description

Chronic hip pain is a common clinical condition, particularly in the elderly, that significantly impairs quality of life and leads to functional limitation and dependence in daily activities. Chronic hip pain caused by degenerative, inflammatory, and mechanical conditions-most notably hip osteoarthritis-often remains inadequately controlled despite medical treatment, physical therapy, and rehabilitation. Although surgical interventions can be effective, they are not suitable for all patients due to advanced age, comorbidities, or surgical contraindications. Therefore, minimally invasive interventional pain management techniques have gained increasing importance in the treatment of chronic hip pain.

The nociceptive innervation of the hip joint primarily arises from the anterior capsule, which is mainly supplied by the sensory branches of the femoral, obturator, and accessory obturator nerves. Based on this anatomical rationale, the pericapsular nerve group (PENG) block is an ultrasound-guided technique that targets these sensory fibers to provide effective analgesia without causing motor blockade. Previous studies have shown that the PENG block reduces pain scores and improves functional mobility in both acute and chronic hip pain; however, its analgesic effect may be time-limited, requiring repeated applications in some patients.

Pulsed radiofrequency (PRF), unlike conventional thermal radiofrequency, aims to modulate nerve transmission without causing tissue destruction and may provide longer-lasting analgesia through neuromodulatory mechanisms. Recent evidence suggests that combining PRF with peripheral nerve blocks may prolong analgesic effects compared with nerve blocks alone. However, prospective studies directly comparing PENG block alone with PENG block combined with PRF in chronic hip pain are limited, highlighting the need for further investigation.

03

Conditions studied

  • Osteoarthritis (OA) of the Hip

Keywords

  • Osteoarthritis, Hip,
  • Pain, Chronic
  • Nerve Blockade
  • Pulsed Radiofrequency Treatment
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

18-80 years old with chronical hip pain

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presence of chronic hip pain lasting at least 3 months
  • Baseline Visual Analog Scale (VAS) score ≥ 4
  • Clinical and/or radiological diagnosis of hip osteoarthritis
  • Inadequate response to conservative treatments

Exclusion criteria

Exclusion Criteria:

  • Local or systemic infection at the intervention site
  • Coagulopathy or inability to discontinue anticoagulant therapy
  • Hip pain related to
  • History of previous hip arthroplasty
  • Severe neurological deficit
  • Pregnancy or breastfeeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
84 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • Group PENG

    The initial step in patients diagnosed with chronic hip pain is a diagnostic intervention, namely the application of a pericapsular nerve group (PENG) block. In patients who benefit from the diagnostic block-defined as a reduction of 50% or more in VAS scores following the procedure-pulsed radiofrequency (PRF) treatment is added as a second-stage intervention. This stepwise approach reflects standard clinical practice, and both procedures are commonly used in clinical praqctice for the management of chronic hip pain. However, the available evidence in the literature on this approach is largely limited to case reports and retrospective case series. The aim of the present study is to document and share the clinical outcomes of this treatment strategy routinely applied in clinical practice.

    Procedure: PENG Block Pulsed radiofrequency

Interventions

  • ProcedurePENG Block Pulsed radiofrequency

    This intervention consists of a stepwise, two-stage treatment protocol routinely applied in our clinical practice for the management of chronic hip pain. In the first stage, all patients undergo an ultrasound-guided pericapsular nerve group (PENG) block as a diagnostic and therapeutic procedure. Pain intensity is assessed using the Visual Analog Scale (VAS) following the diagnostic block. Only patients who demonstrate a clinically meaningful response, defined as a reduction of 50% or greater in VAS scores, proceed to the second stage of the intervention. In the second stage, pulsed radiofrequency (PRF) treatment is applied to the same target region in addition to the PENG block, aiming to achieve longer-lasting analgesia through neuromodulation without tissue destruction.

06

What researchers measure

Primary outcomes

  1. Change in pain intensity measured by the Visual Analog Scale (VAS, 0-10; higher scores indicate worse pain)

    Pain intensity will be assessed using the Visual Analog Scale (VAS), a validated pain measurement tool ranging from 0 to 10, where 0 indicates no pain and 10 represents the worst pain imaginable.

    Time frame: baseline (pre-procedure) and at 1 week, 1 month, 3 months, and 6 months after the procedure.

Secondary outcomes

  1. Change in Pain, Stiffness, and Physical Function Measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC, 0-96)

    Pain, stiffness, and physical function were assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC; total score range 0-96, with higher scores indicating worse symptoms and functional limitation). The change in WOMAC total score from baseline to 1 month following pulsed radiofrequency (PRF) treatment was evaluated as a secondary outcome. Additional analyses included changes in WOMAC subscale scores (pain, stiffness, and physical function) at 1 week, 3 months, and 6 months post-intervention. A clinically meaningful improvement was defined as a ≥20% reduction in the total WOMAC score compared with baseline.

    Time frame: baseline (pre-procedure) and at 1 week, 1 month, 3 months, and 6 months after the procedure.

  2. Change in Hip Function Measured by the Harris Hip Score (HHS, 0-100)

    Hip pain and functional status were evaluated using the Harris Hip Score (HHS; total score range 0-100, with higher scores indicating better hip function). The HHS assesses four domains: pain, function (activities of daily living and gait), absence of deformity, and range of motion. The change in total HHS from baseline to 1 month after pulsed radiofrequency (PRF) treatment was analyzed as a secondary outcome. Additional assessments were performed at 1 week, 3 months, and 6 months post-intervention to evaluate the sustainability of functional improvement. A clinically meaningful improvement was defined as an increase of ≥10 points in the total HHS compared with baseline.

    Time frame: Baseline (pre-procedure), 1 week, 1 month (primary functional endpoint), 3 months, and 6 months after pulsed radiofrequency (PRF) treatment.

  3. Secondary Outcome: TAnalgesic Use

    The following parameters were evaluated as secondary outcomes: Analgesic consumption: Changes in daily analgesic dose and frequency of use were recorded and compared between baseline and post-intervention follow-up visits.

    Time frame: Baseline and at 1 week, 1 month, 3 months, and 6 months post-intervention

07

Study locations

1 of 1 sites recruiting
  • Ankara Bilkent City Hospital
    Ankara, 06680, Turkey (Türkiye)
    Recruiting
    • Ulku Sabuncu Assoc. Prof. · Contact905337085212
08

References and documents

Publications

  • Jadon A. Pulsed Radiofrequency (PRF) of Pericapsular Nerves Group (PENG) in Chronic Hip Pain-A Case Report. Turk J Anaesthesiol Reanim. 2021 Dec;49(6):490-493. doi: 10.5152/TJAR.2021.1080. PubMed 35110031 ↗
  • 10.5152/TJAR.2021.21230

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Feb 2027, 12 months after the start.

Of 146 non-industry observational studies under Osteoarthritis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 97. This study's planned 12 months is below that.

Counting every sponsor, half of 228 studies reached it within 57 months; a quarter within 21 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2026
First posted
Jan 22, 2026
StartActual
Feb 1, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 28, 2027
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07360093
Responsible party
Ülkü Sabuncu (Assoc. Prof., Ankara City Hospital Bilkent) — Principal investigator
First posted
Jan 22, 2026
Start date
Feb 1, 2026
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Mar 18, 2026

Study contacts

Ulku Sabuncu MD, Assoc. prof.
Contact
sabuncuulku@gmail.com
+905337085212

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion